Elotuzumab , an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F@ ( SLAMF@ ) , showed activity in combination with lenalidomide and dexamethasone in a phase @b-@ study in patients with relapsed or refractory multiple myeloma .